0001193125-26-149599
SEC filingQ3 revenue declined 4.4% to $211.2M amid divestitures and discontinued products, with gross margin contracting to 46.9% from volume decreases, inventory write-offs, and Petrifilm manufacturing transition costs, driving operating losses despite strong $53.0M operating cash flow.
Revenue decreased 4.4% to $211.2 million from $221.0 million in the prior-year quarter, primarily due to lower sales volumes following the divestiture of the Cleaners and Disinfectants business. This reflects the strategic shift away from non-core operations, with the impact compounded by discontinued products, though core business dynamics like volume pressures persisted.
Gross profit fell 10.2% to $99.0 million, compressing the gross margin to 46.9% from higher levels last year. The decrease in margin was primarily due to volume decreases, higher inventory write-offs, and duplicative costs as the company prepares to manufacture Petrifilm products internally. Additionally, fiscal years 2025 and 2026 saw elevated inventory write-offs from expiration of certain inventory at international locations, stemming from supply chain and distribution challenges in fiscal 2024. These factors highlight transitional pressures in production and inventory management, even as management focuses on enhancing operational efficiency.
Operating income shifted to a $3.3 million loss from a $5.4 million profit, yielding an operating margin of -1.6%. This swing was driven by the gross profit decline alongside increases in operating expenses. The increase in both comparable periods was primarily driven by investments in transformation initiatives, transaction costs, and compensation-related costs, partially offset by reduced costs from the divested Cleaners and Disinfectants business and lower professional service expenses. Inventory reductions reflect management’s focus on operational efficiency, contributing positively to cash dynamics despite the loss. This underscores aggressive cost realignment amid restructuring, with Petrifilm ramp-up and divestiture effects dominating the period.
Net income deteriorated to a $17.0 million loss from $11.0 million, with diluted EPS at -$0.08 versus -$0.05, as operating losses compounded by other expenses including interest widened the gap. Operating cash flow strengthened to $53.0 million from $41.7 million, supported by inventory reductions and proceeds from the Cleaners sale, alongside lower capital expenditures as the new Lansing facility nears completion. This signals underlying cash generation resilience.
Looking ahead, continued improvement is expected for the remainder of FY2026, though supplier issues in Animal Safety and Petrifilm transition impacts may persist into early FY2027. These dynamics position Neogen for efficiency gains post-transition, with divestitures streamlining the portfolio.